Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 7/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364960 | 1.00 | TRPA1 (0.36) | TRPA1PIK3CDGPER1IDO1TDO2 | |
| SCHEMBL29347889 | 0.83 | — | — | |
| SCHEMBL24365687 | 0.82 | PIK3CD (0.41) | PIK3CDIDO1TDO2ACACBNAMPT | |
| SCHEMBL30551259 | 0.82 | PIK3CD (0.46) | TRPA1PIK3CDGPER1ROCK2RPS6KB1 | |
| SCHEMBL29477605 | 0.82 | PIK3CD (0.41) | PIK3CDIDO1TDO2ACACBNAMPT | |
| SCHEMBL25322160 | 0.82 | PIK3CD (0.46) | TRPA1PIK3CDGPER1ROCK2RPS6KB1 | |
| SCHEMBL29477676 | 0.82 | PIK3CD (0.46) | TRPA1PIK3CDGPER1ROCK2RPS6KB1 | |
| SCHEMBL24365179 | 0.82 | PIK3CD (0.46) | TRPA1PIK3CDGPER1ROCK2RPS6KB1 | |
| SCHEMBL29081299 | 0.78 | CREBBP (0.39) | IDO1TDO2 | |
| SCHEMBL30470303 | 0.78 | CREBBP (0.39) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TRPA1 848/4885PIK3CD 4481/4885GPER1 370/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TRPA1 1663/4885PIK3CD 3800/4885GPER1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.